Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD.
Haron Avgana, Roni Shira Toledano, Irit Akirav
Pharmaceuticals June 27, 2024 DOI: 10.3390/ph17070846 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical study Peer reviewed |
|---|---|
| Population | Male rats |
| Interventions | OXT-R antagonist L-368 899 |
| Topics | MDMA PTSD |
| Keywords | Fear extinction Neuroinflammation Oxytocin MDMA Therapy Ecstasy Trauma therapy Neurological studies Fear learning Brain chemistry |
| Citations | 8 |
| Key points | MDMA's therapeutic effects in a PTSD rat model are associated with restored oxytocin receptor expression and reduced neuroinflammation, and its effects on extinction and anxiety may be mediated by oxytocinergic signaling. |
Abstract
MDMA-assisted psychotherapy has shown potential as an effective treatment for post-traumatic stress disorder (PTSD). Preclinical studies involving rodents have demonstrated that MDMA can facilitate the extinction of fear memories. It has been noted that MDMA impacts oxytocin neurons and pro-inflammatory cytokines. Thus, the aim of this study was to explore the role of oxytocinergic signaling and neuroinflammatory markers in the therapeutic effects of MDMA. To achieve this, male rats were subjected to a model of PTSD involving exposure to shock and situational reminders. MDMA was microinjected into the medial prefrontal cortex (mPFC) before extinction training, followed by behavioral tests assessing activity levels, anxiety, and social function. Our findings indicate that MDMA treatment facilitated fear extinction and mitigated the shock-induced increase in freezing, as well as deficits in social behavior. Shock exposure led to altered expression of the gene coding for OXT-R and neuroinflammation in the mPFC and basolateral amygdala (BLA), which were restored by MDMA treatment. Importantly, the OXT-R antagonist L-368,899 prevented MDMA's therapeutic effects on extinction and freezing behavior. In conclusion, MDMA's therapeutic effects in the PTSD model are associated with alterations in OXT-R expression and neuroinflammation, and MDMA's effects on extinction and anxiety may be mediated by oxytocinergic signaling.
Comparable studies
Other preclinical and animal studies on MDMA for PTSD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats Rats exposed to predator-scent stress | 2022 | Controlled prospective study | |
| Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents Rodents | 2024 | Review | |
| MDMA administration attenuates hippocampal IL-β immunoreactivity and subsequent stress-enhanced fear learning: An animal model of PTSD Male rats | 2022 | Preclinical study | |
| Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA Rats | 2024 | Preclinical study | |
| Discriminative stimulus properties of α-ethyltryptamine (α-ET) in rats: α-ET-like effects of MDMA, MDA and aryl-monomethoxy substituted derivatives of α-ET. Rats | 2025 | Drug discrimination study |
Citations in the library
Cited by 6
- Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents Neuroscience & Biobehavioral Reviews September 20, 2024
- How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder. Drugs November 1, 2024
- The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans. Neuroscience & Biobehavioral Reviews October 1, 2025
- MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst? Translation The University of Toledo Journal of Medical Sciences February 17, 2026
- MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions Psychedelics October 14, 2025
and 1 more in the library
Cites 28
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacology March 3, 2006
- Oxytocin-dependent reopening of a social reward learning critical period with MDMA Nature April 3, 2019
and 23 more in the library